
Pharmaceuticals North America (NAFTA) Industry Guide 2019-2028
Description
Pharmaceuticals North America (NAFTA) Industry Guide 2019-2028
Summary
The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The pharmaceuticals industry within the NAFTA countries had a total market value of $546.6 billion in 2023.The Mexico was the fastest growing country, with a CAGR of 7% over the 2019-23 period.
- Within the pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $496.7 billion in 2023. This was followed by Canada and Mexico, with a value of $32.3 and $17.7 billion, respectively.
- The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of $579.7 billion in 2028, followed by Canada and Mexico with expected values of $37.7 and $22.5 billion, respectively.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA pharmaceuticals market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA pharmaceuticals market
- Leading company profiles reveal details of key pharmaceuticals market players’ NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA pharmaceuticals market with five year forecasts
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country
- What was the size of the NAFTA pharmaceuticals market by value in 2023?
- What will be the size of the NAFTA pharmaceuticals market in 2028?
- What factors are affecting the strength of competition in the NAFTA pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitors in the NAFTA pharmaceuticals market?
Table of Contents
286 Pages
- 1 Introduction
- 1.1. What is this report about?
- 1.2. Who is the target reader?
- 1.3. How to use this report
- 1.4. Definitions
- 2 NAFTA Pharmaceuticals
- 2.1. Industry Outlook
- 3 Pharmaceuticals in Canada
- 3.1. Market Overview
- 3.2. Market Data
- 3.3. Market Segmentation
- 3.4. Market outlook
- 3.5. Five forces analysis
- 4 Macroeconomic Indicators
- 4.1. Country data
- 5 Pharmaceuticals in Mexico
- 5.1. Market Overview
- 5.2. Market Data
- 5.3. Market Segmentation
- 5.4. Market outlook
- 5.5. Five forces analysis
- 6 Macroeconomic Indicators
- 6.1. Country data
- 7 Pharmaceuticals in The United States
- 7.1. Market Overview
- 7.2. Market Data
- 7.3. Market Segmentation
- 7.4. Market outlook
- 7.5. Five forces analysis
- 8 Macroeconomic Indicators
- 8.1. Country data
- 9 Company Profiles
- 9.1. BASF SE
- 9.2. Sinopharm Group Co Ltd
- 9.3. F. Hoffmann-La Roche Ltd
- 9.4. The Procter & Gamble Co
- 9.5. Shanghai Pharmaceuticals Holding Co Ltd
- 9.6. CSPC Pharmaceutical Group Ltd
- 9.7. Takeda Pharmaceutical Co Ltd
- 9.8. Novartis AG
- 9.9. GSK plc
- 9.10. AstraZeneca Plc
- 9.11. Sanofi
- 9.12. Roche Holding AG
- 9.13. Laboratoires Pierre Fabre SA
- 9.14. Ipsen SA
- 9.15. Les Laboratoires Servier SAS
- 9.16. Bayer AG
- 9.17. Boehringer Ingelheim GmbH
- 9.18. CSL Ltd
- 9.19. Astrazeneca Pty Ltd
- 9.20. Mayne Pharma Group Ltd
- 9.21. Hypera SA
- 9.22. Ache Laboratorios Farmaceuticos SA
- 9.23. EMS Sigma Pharma
- 9.24. Eurofarma Laboratorios SA
- 9.25. Johnson & Johnson
- 9.26. Sanofi-Aventis Canada Inc
- 9.27. Apotex Inc
- 9.28. Bausch Health Companies Inc
- 9.29. Jiangsu Hengrui Medicine Co Ltd
- 9.30. Lupin Ltd
- 9.31. Cipla Ltd
- 9.32. Dr. Reddy's Laboratories Ltd
- 9.33. PT Kalbe Farma Tbk
- 9.34. PT Kimia Farma Tbk
- 9.35. PT Tempo Scan Pacific Tbk
- 9.36. Pfizer Italia Srl
- 9.37. A. Menarini Industrie Farmaceutiche Riunite Srl
- 9.38. Chiesi Farmaceutici SpA
- 9.39. Recordati SpA
- 9.40. Daiichi Sankyo Co Ltd
- 9.41. Astellas Pharma Inc
- 9.42. Otsuka Holdings Co Ltd
- 9.43. Sanofi-Aventis de Mexico SA de CV
- 9.44. Genomma Lab Internacional SAB de CV
- 9.45. Bayer de Mexico SA de CV
- 9.46. Boehringer Ingelheim Mexico
- 9.47. Pfizer BV
- 9.48. Astellas Pharma Europe Ltd
- 9.49. Merck & Co Inc
- 9.50. AbbVie Inc
- 9.51. Pfizer Inc
- 9.52. Bristol-Myers Squibb Co
- 9.53. OTC Pharma International BV
- 9.54. Pharmstandard
- 9.55. Binnopharm Group
- 9.56. Novo Nordisk AS
- 9.57. H. Lundbeck AS
- 9.58. Pfizer Laboratories (Pty) Ltd
- 9.59. Aspen Pharmacare Holdings Ltd
- 9.60. Adcock Ingram Holdings Ltd
- 9.61. Chong Kun Dang Pharmaceutical Corp.
- 9.62. Yuhan Corp
- 9.63. Celltrion Inc
- 9.64. Hanmi Pharmaceuticals Co Ltd
- 9.65. Grifols SA
- 9.66. Almirall SA
- 9.67. Laboratorios Farmaceuticos Rovi SA
- 9.68. Abdi Ibrahim Ilac Sanayi ve Ticaret AS
- 9.69. Deva Holding AS
- 10 Appendix
- 10.1. Methodology
- 10.2. About MarketLine
- List of Tables
- Table 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2019-28
- Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2019-23
- Table 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2023-28
- Table 4: Canada pharmaceuticals market value: $ billion, 2018-23
- Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2023
- Table 6: Canada pharmaceuticals market value forecast: $ billion, 2023-28
- Table 7: Canada Size of Population (million), 2019-23
- Table 8: Canada real GDP (Constant 2010 Prices, $ billion), 2019-23
- Table 9: Canada GDP (Current Prices, $ Billion), 2019-23
- Table 10: Canada Inflation, 2019-23
- Table 11: Canada Consumer Price Index (Absolute), 2019-23
- Table 12: Canada exchange rate, 2018-23
- Table 13: Mexico pharmaceuticals market value: $ billion, 2018-23
- Table 14: Mexico pharmaceuticals market geography segmentation: $ billion, 2023
- Table 15: Mexico pharmaceuticals market value forecast: $ billion, 2023-28
- Table 16: Mexico Size of Population (million), 2019-23
- Table 17: Mexico real GDP (Constant 2010 Prices, $ billion), 2019-23
- Table 18: Mexico GDP (Current Prices, $ Billion), 2019-23
- Table 19: Mexico Inflation, 2019-23
- Table 20: Mexico Consumer Price Index (Absolute), 2019-23
- Table 21: Mexico exchange rate, 2018-23
- Table 22: United States pharmaceuticals market value: $ billion, 2018-23
- Table 23: United States pharmaceuticals market geography segmentation: $ billion, 2023
- Table 24: United States pharmaceuticals market value forecast: $ billion, 2023-28
- Table 25: United States Size of Population (million), 2019-23
- Table 26: United States real GDP (Constant 2010 Prices, $ billion), 2019-23
- Table 27: United States GDP (Current Prices, $ Billion), 2019-23
- Table 28: United States Inflation, 2019-23
- Table 29: United States Consumer Price Index (Absolute), 2019-23
- Table 30: United States exchange rate, 2018-23
- Table 31: BASF SE: key facts
- Table 32: BASF SE: Annual Financial Ratios
- Table 33: BASF SE: Key Employees
- Table 34: Sinopharm Group Co Ltd: key facts
- Table 35: Sinopharm Group Co Ltd: Annual Financial Ratios
- Table 36: Sinopharm Group Co Ltd: Key Employees
- Table 37: F. Hoffmann-La Roche Ltd: key facts
- Table 38: F. Hoffmann-La Roche Ltd: Key Employees
- Table 39: The Procter & Gamble Co: key facts
- Table 40: The Procter & Gamble Co: Annual Financial Ratios
- Table 41: The Procter & Gamble Co: Key Employees
- Table 42: The Procter & Gamble Co: Key Employees Continued
- Table 43: Shanghai Pharmaceuticals Holding Co Ltd: key facts
- Table 44: Shanghai Pharmaceuticals Holding Co Ltd: Annual Financial Ratios
- Table 45: Shanghai Pharmaceuticals Holding Co Ltd: Key Employees
- Table 46: CSPC Pharmaceutical Group Ltd: key facts
- Table 47: CSPC Pharmaceutical Group Ltd: Annual Financial Ratios
- Table 48: CSPC Pharmaceutical Group Ltd: Key Employees
- Table 49: Takeda Pharmaceutical Co Ltd: key facts
- Table 50: Takeda Pharmaceutical Co Ltd: Annual Financial Ratios
- Table 51: Takeda Pharmaceutical Co Ltd: Key Employees
- Table 52: Takeda Pharmaceutical Co Ltd: Key Employees Continued
- Table 53: Novartis AG: key facts
- Table 54: Novartis AG: Annual Financial Ratios
- Table 55: Novartis AG: Key Employees
- Table 56: GSK plc: key facts
- Table 57: GSK plc: Annual Financial Ratios
- Table 58: GSK plc: Key Employees
- Table 59: AstraZeneca Plc: key facts
- Table 60: AstraZeneca Plc: Annual Financial Ratios
- Table 61: AstraZeneca Plc: Key Employees
- Table 62: Sanofi: key facts
- Table 63: Sanofi: Annual Financial Ratios
- Table 64: Sanofi: Key Employees
- Table 65: Sanofi: Key Employees Continued
- Table 66: Roche Holding AG: key facts
- Table 67: Roche Holding AG: Annual Financial Ratios
- Table 68: Roche Holding AG: Key Employees
- Table 69: Laboratoires Pierre Fabre SA: key facts
- Table 70: Laboratoires Pierre Fabre SA: Key Employees
- Table 71: Ipsen SA: key facts
- Table 72: Ipsen SA: Annual Financial Ratios
- Table 73: Ipsen SA: Key Employees
- Table 74: Ipsen SA: Key Employees Continued
- Table 75: Les Laboratoires Servier SAS: key facts
- Table 76: Les Laboratoires Servier SAS: Key Employees
- Table 77: Bayer AG: key facts
- Table 78: Bayer AG: Annual Financial Ratios
- Table 79: Bayer AG: Key Employees
- Table 80: Bayer AG: Key Employees Continued
- Table 81: Boehringer Ingelheim GmbH: key facts
- Table 82: Boehringer Ingelheim GmbH: Key Employees
- Table 83: CSL Ltd: key facts
- Table 84: CSL Ltd: Annual Financial Ratios
- Table 85: CSL Ltd: Key Employees
- Table 86: Astrazeneca Pty Ltd: key facts
- Table 87: Astrazeneca Pty Ltd: Key Employees
- Table 88: Mayne Pharma Group Ltd: key facts
- Table 89: Mayne Pharma Group Ltd: Annual Financial Ratios
- Table 90: Mayne Pharma Group Ltd: Key Employees
- Table 91: Hypera SA: key facts
- Table 92: Hypera SA: Annual Financial Ratios
- Table 93: Hypera SA: Key Employees
- List of Figures
- Figure 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2019-28
- Figure 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2019-23
- Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2023-28
- Figure 4: Canada pharmaceuticals market value: $ billion, 2018-23
- Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2023
- Figure 6: Canada pharmaceuticals market value forecast: $ billion, 2023-28
- Figure 7: Forces driving competition in the pharmaceuticals market in Canada, 2023
- Figure 8: Drivers of buyer power in the pharmaceuticals market in Canada, 2023
- Figure 9: Drivers of supplier power in the pharmaceuticals market in Canada, 2023
- Figure 10: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2023
- Figure 11: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2023
- Figure 12: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2023
- Figure 13: Mexico pharmaceuticals market value: $ billion, 2018-23
- Figure 14: Mexico pharmaceuticals market geography segmentation: % share, by value, 2023
- Figure 15: Mexico pharmaceuticals market value forecast: $ billion, 2023-28
- Figure 16: Forces driving competition in the pharmaceuticals market in Mexico, 2023
- Figure 17: Drivers of buyer power in the pharmaceuticals market in Mexico, 2023
- Figure 18: Drivers of supplier power in the pharmaceuticals market in Mexico, 2023
- Figure 19: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2023
- Figure 20: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2023
- Figure 21: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2023
- Figure 22: United States pharmaceuticals market value: $ billion, 2018-23
- Figure 23: United States pharmaceuticals market geography segmentation: % share, by value, 2023
- Figure 24: United States pharmaceuticals market value forecast: $ billion, 2023-28
- Figure 25: Forces driving competition in the pharmaceuticals market in the United States, 2023
- Figure 26: Drivers of buyer power in the pharmaceuticals market in the United States, 2023
- Figure 27: Drivers of supplier power in the pharmaceuticals market in the United States, 2023
- Figure 28: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2023
- Figure 29: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2023
- Figure 30: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.